At present, our study provided some evidence that WBE as an effective add-on treatment based on GC+ISA, may be superior to current second-line therapy of IVIG/RTX in refractory severe SLE-AIHA, especially in those with a Hb lower than 40 g/L. Here, GSTM1 is linked to autoimmune hemolytic anemia.